Investigation of Cross-reactivity Between Phenobarbital and Levetiracetam in Children with Epilepsy: A Prospective, Observational Multicenter Study

Overview

Journal Epilepsy Behav Rep

Specialty Psychology

Date 2023 Jan 23

PMID 36685756

Authors

Samane Rahimi

Bardia Danaei

Mohammad Mehdi Nasehi

Sasan Saket

Nazanin Farahbakhsh

Maryam Rajabnejad

Mohammad Mehdi Taghdiri

Affiliations

Soon will be listed here.

Abstract

Objectives: Pharmaceutical allergic reactions due to antiseizure medications (ASMs) are one of the major concerns in the management of patients. Finding an alternative ASM which does not cause allergic reactions and has acceptable effectiveness can be difficult. In this regard, the present study attempts to investigate the cross-reactivity between phenobarbital and levetiracetam in children under treatment for seizure control.

Materials & Methods: The present study is a prospective, observational independent assessor study. 30 children with epilepsy who were hypersensitive to phenobarbital therapy were studied. In order to evaluate the cross-reactivity of the drugs, levetiracetam replaced phenobarbital to control seizure. Within 6 months, any allergic reactions and seizure recurrences were evaluated in the patients.

Results: 53 % of the children in this study were female. The mean age of patients was 42.4 months. In patients' follow up no cross-reactive responses were observed in any of the patients. Seizure recurrence rate was 30 % in the first six months of follow up that with increasing dosage in the second six months of follow-up, decreased to 10 %.

Conclusion: Based on the results of this study, in children with epilepsy controlled by phenobarbital if allergic reactions to phenobarbital occur, levetiracetam may be used as a suitable alternative medicine.

Citing Articles

Nanosensors in the detection of antihypertension drugs, a golden step for medication adherence monitoring.

Mobed A, Gholami S, Tahavvori A, Ghazi F, Masoumi Z, Alipourfard I Heliyon. 2023; 9(9):e19467.

PMID: 37810167 PMC: 10558620. DOI: 10.1016/j.heliyon.2023.e19467.

References

Hertl M, Merk H . Lymphocyte activation in cutaneous drug reactions. J Invest Dermatol. 1995; 105(1 Suppl):95S-98S. DOI: 10.1038/jid.1995.19. View

Panda S . Cross-sensitivity of Levetiracetam and Carbamazepine Induced Skin Rash. J Assoc Physicians India. 2019; 67(4):89-90. View

Kim H, Kim D, Bae E, Kim D . Adverse Skin Reactions with Antiepileptic Drugs Using Korea Adverse Event Reporting System Database, 2008-2017. J Korean Med Sci. 2020; 35(4):e17. PMC: 6995813. DOI: 10.3346/jkms.2020.35.e17. View

Bergmann M, Villard J, Caubet J . [Genetic predispositions in drug allergy: the role of HLA]. Rev Med Suisse. 2014; 10(426):864-8. View

Lyseng-Williamson K . Levetiracetam: a review of its use in epilepsy. Drugs. 2011; 71(4):489-514. DOI: 10.2165/11204490-000000000-00000. View

Alkhotani A, McLachlan R . Levetiracetam induced angioedema in a patient with previous anticonvulsant hypersensitivity reaction to phenytoin and lamotrigine. Seizure. 2012; 21(5):407-8. DOI: 10.1016/j.seizure.2012.03.007. View

Pal D . Phenobarbital for childhood epilepsy: systematic review. Paediatr Perinat Drug Ther. 2007; 7(1):31-42. PMC: 1820948. DOI: 10.1185/146300905X75361. View

Grosso S, Franzoni E, Coppola G, Iannetti P, Verrotti A, Cordelli D . Efficacy and safety of levetiracetam: an add-on trial in children with refractory epilepsy. Seizure. 2005; 14(4):248-53. DOI: 10.1016/j.seizure.2005.02.004. View

Zhang J, Li X, Su Y, Sun M, Wang J, Hao Y . Association between gene polymorphism and cutaneous adverse reactions caused by antiepileptic drugs. Exp Ther Med. 2018; 15(4):3399-3403. PMC: 5840917. DOI: 10.3892/etm.2018.5801. View

10.

Vittorio C, Muglia J . Anticonvulsant hypersensitivity syndrome. Arch Intern Med. 1995; 155(21):2285-90. View

11.

Kothare S, Kaleyias J . The adverse effects of antiepileptic drugs in children. Expert Opin Drug Saf. 2007; 6(3):251-65. DOI: 10.1517/14740338.6.3.251. View

12.

Wang X, Lang S, Shi X, Tian H, Wang R, Yang F . Cross-reactivity of skin rashes with current antiepileptic drugs in Chinese population. Seizure. 2010; 19(9):562-6. DOI: 10.1016/j.seizure.2010.09.003. View

13.

Shear N, Spielberg S . Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. J Clin Invest. 1988; 82(6):1826-32. PMC: 442760. DOI: 10.1172/JCI113798. View

14.

Wang J, Zhang J, Wu X, Yu P, Hong Z . HLA-B*1502 allele is associated with a cross-reactivity pattern of cutaneous adverse reactions to antiepileptic drugs. J Int Med Res. 2012; 40(1):377-82. DOI: 10.1177/147323001204000140. View

15.

Vandebriel R . Gene polymorphisms within the immune system that may underlie drug allergy. Naunyn Schmiedebergs Arch Pharmacol. 2003; 369(1):125-32. DOI: 10.1007/s00210-003-0804-6. View

16.

Rizvi S, Ladino L, Hernandez-Ronquillo L, Tellez-Zenteno J . Epidemiology of early stages of epilepsy: Risk of seizure recurrence after a first seizure. Seizure. 2017; 49:46-53. DOI: 10.1016/j.seizure.2017.02.006. View

17.

Franceschini F, Bottau P, Caimmi S, Cardinale F, Crisafulli G, Liotti L . Mechanisms of hypersensitivity reactions induced by drugs. Acta Biomed. 2019; 90(3-S):44-51. PMC: 6502177. DOI: 10.23750/abm.v90i3-S.8160. View

18.

Ramos-Lizana J, Aguilera-Lopez P, Aguirre-Rodriguez J, Cassinello-Garcia E . Early prediction of refractory epilepsy in childhood. Seizure. 2009; 18(6):412-6. DOI: 10.1016/j.seizure.2009.02.006. View

19.

Crisafulli G, Franceschini F, Caimmi S, Bottau P, Liotti L, Saretta F . Mild cutaneous reactions to drugs. Acta Biomed. 2019; 90(3-S):36-43. PMC: 6502176. DOI: 10.23750/abm.v90i3-S.8159. View

20.

Fisher R, Cross J, French J, Higurashi N, Hirsch E, Jansen F . Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017; 58(4):522-530. DOI: 10.1111/epi.13670. View